TY - JOUR
T1 - Effect of human acellular dermal matrix (Megaderm™) on infra-auricular depressed deformities, Frey’s syndrome, and first bite syndrome following parotidectomy
T2 - a multi-center prospective study
AU - Kim, Joo Hyun
AU - Hee Kim, Da
AU - Lim, Jae Yol
AU - Won, Ho Ryun
AU - Seob Shin, Yoo
AU - Kim, Chul Ho
AU - Ban, Myung Jin
AU - Hong Park, Jae
AU - Kwon Byeon, Hyung
AU - Jun Hong, Hyun
AU - Choi, Eun Chang
AU - Yoo Koh, Woon
N1 - Funding Information:
Funding: This study was supported by a faculty research
Publisher Copyright:
© 2021, Gland Surgery. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Background: Parotidectomy is the primary treatment for parotid gland tumors. However, complications may include a prominent facial scar or infra-auricular depressed deformity, Frey’s syndrome, first bite syndrome, or other facial pain, numbness, and paralysis. Acellular dermal matrix (ADM) has been widely used to prevent these complications in parotid surgery, but there have been no prospective, multi-center trials documenting its efficacy. This study evaluates the effectiveness of ADM implantation in preventing infra-auricular depressed deformity, Frey’s syndrome and first bite syndrome after parotidectomy. Methods: We analyzed 51 cases of standard parotidectomy and 58 cases of parotidectomy with implantation of Megaderm™ ADM through prospective multicenter trial. Acute complications including infection, seroma, hematoma, skin necrosis, and acute parotid area pain were evaluated 1 week postoperatively. Clinician grading of Frey’s syndrome and blinded clinician evaluation of infra-auricular depressed deformities were conducted at 3, 6, and 12 months. Patients evaluated subjective satisfaction with neck appearance, Frey’s syndrome quality, and acute parotid area pain at 3, 6, and 12 months. Results: There was a higher incidence of seroma in the Megaderm™ group than in the control group at week 1. The incidence and total clinician-evaluated Frey’s syndrome scores were significantly lower in the Megaderm™ group than in the control group at 3, 6, and 12 months. Both the objective and subjective evaluations of the facial contour showed a better outcome in the Megaderm™ group compared to the control group at 3, 6, and 12 months. There were no significant differences between the groups in the patient-reported Frey’s syndrome quality scores at 3, 6, and 12 months, but the Megaderm™ group reported significantly less acute pain than the control group. Conclusions: ADM implantation can effectively reduce the occurrence of Frey’s syndrome, infra-auricular depressed deformity, and first bite syndrome after parotidectomy. ADM may be especially advantageous in complex parotidectomy cases when significant complications are expected.
AB - Background: Parotidectomy is the primary treatment for parotid gland tumors. However, complications may include a prominent facial scar or infra-auricular depressed deformity, Frey’s syndrome, first bite syndrome, or other facial pain, numbness, and paralysis. Acellular dermal matrix (ADM) has been widely used to prevent these complications in parotid surgery, but there have been no prospective, multi-center trials documenting its efficacy. This study evaluates the effectiveness of ADM implantation in preventing infra-auricular depressed deformity, Frey’s syndrome and first bite syndrome after parotidectomy. Methods: We analyzed 51 cases of standard parotidectomy and 58 cases of parotidectomy with implantation of Megaderm™ ADM through prospective multicenter trial. Acute complications including infection, seroma, hematoma, skin necrosis, and acute parotid area pain were evaluated 1 week postoperatively. Clinician grading of Frey’s syndrome and blinded clinician evaluation of infra-auricular depressed deformities were conducted at 3, 6, and 12 months. Patients evaluated subjective satisfaction with neck appearance, Frey’s syndrome quality, and acute parotid area pain at 3, 6, and 12 months. Results: There was a higher incidence of seroma in the Megaderm™ group than in the control group at week 1. The incidence and total clinician-evaluated Frey’s syndrome scores were significantly lower in the Megaderm™ group than in the control group at 3, 6, and 12 months. Both the objective and subjective evaluations of the facial contour showed a better outcome in the Megaderm™ group compared to the control group at 3, 6, and 12 months. There were no significant differences between the groups in the patient-reported Frey’s syndrome quality scores at 3, 6, and 12 months, but the Megaderm™ group reported significantly less acute pain than the control group. Conclusions: ADM implantation can effectively reduce the occurrence of Frey’s syndrome, infra-auricular depressed deformity, and first bite syndrome after parotidectomy. ADM may be especially advantageous in complex parotidectomy cases when significant complications are expected.
UR - http://www.scopus.com/inward/record.url?scp=85102075644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102075644&partnerID=8YFLogxK
U2 - 10.21037/gs-20-703
DO - 10.21037/gs-20-703
M3 - Article
AN - SCOPUS:85102075644
VL - 10
SP - 670
EP - 677
JO - Gland Surgery
JF - Gland Surgery
SN - 2227-684X
IS - 1
ER -